VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COMy Virtual 2020 | Novel drugs for myeloma thromboprophylaxis

Heinz Ludwig • 13 May 2020
COMy Virtual 2020
Multiple Myeloma Apixaban Edoxaban

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, talks on myeloma thromboprophylaxis, specifically, the use of novel anticoagulants such as edoxaban and apixaban. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Heinz Ludwig

1:51
PTC596: inhibiting BMI1 in myeloma
Heinz Ludwig • 12 May 2020
1:58
Why we have to be especially aware of infection in patients with myeloma
Heinz Ludwig • 27 Jan 2017
3:14
UVEA-IXA: ixazomib-based therapy in R/R myeloma treated via European early access program
Heinz Ludwig • 2 Jun 2020
8:44
Novel therapies in myeloma: selinexor, venetoclax, among others
Heinz Ludwig et al. • 27 Jan 2017

Related Videos

4:55
Maintenance therapy in young patients with myeloma
Graham Jackson • 5 Mar 2021
3:25
BVD in heavily pretreated multiple myeloma
Claudio Cerchione • 3 Mar 2021
1:41
#woMMen: network of women in multiple myeloma
Nina Shah • 3 Mar 2021
3:08
Frailty subgroup analysis of the MAIA trial
Gordon Cook • 2 Mar 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals